Exploring biomarkers to predict clinical improvement of atopic dermatitis in patients treated with dupilumab (B-PAD study)

Takeshi Nakahara; Kenji Izuhara; Daisuke Onozuka; Hidehisa Saeki; Satoshi Nunomura; Motoi Takenaka; Mai Matsumoto; Yoko Kataoka; Rai Fujimoto; Sakae Kaneko; Eishin Morita; Akio Tanaka; Michihiro Hide; Tatsuro Okano; Tomomitsu Miyagaki; Natsuko Aoki; Kimiko Nakajima; Susumu Ichiyama; Makiko Kido-Nakahara; Kyoko Tonomura; Yukinobu Nakagawa; Risa Tamagawa-Mineoka; Koji Masuda; Takuya Takeichi; Masashi Akiyama; Yozo Ishiuji; Michie Katsuta; Yuki Kinoshita; Chiharu Tateishi; Aya Yamamoto; Akimichi Morita; Haruna Matsuda-Hirose; Yutaka Hatano; Hiroshi Kawasaki; Keiji Tanese; Mamitaro Ohtsuki; Koji Kamiya; Yudai Kabata; Riichiro Abe; Hiroshi Mitsui; Tatsuyoshi Kawamura; Gaku Tsuji; Norito Katoh; Masutaka Furue

doi:10.1111/cea.14267

Exploring biomarkers to predict clinical improvement of atopic dermatitis in patients treated with dupilumab (B-PAD study)

Clin Exp Allergy. 2023 Feb;53(2):233-238. doi: 10.1111/cea.14267. Epub 2022 Dec 16.

Authors

Takeshi Nakahara¹, Kenji Izuhara², Daisuke Onozuka³, Hidehisa Saeki⁴, Satoshi Nunomura², Motoi Takenaka⁵, Mai Matsumoto⁵, Yoko Kataoka⁶, Rai Fujimoto⁶, Sakae Kaneko⁷, Eishin Morita⁷, Akio Tanaka⁸, Michihiro Hide⁸, Tatsuro Okano⁹, Tomomitsu Miyagaki⁹, Natsuko Aoki¹⁰, Kimiko Nakajima¹⁰, Susumu Ichiyama⁴, Makiko Kido-Nakahara¹, Kyoko Tonomura¹¹, Yukinobu Nakagawa¹¹, Risa Tamagawa-Mineoka¹², Koji Masuda¹², Takuya Takeichi¹³, Masashi Akiyama¹³, Yozo Ishiuji¹⁴, Michie Katsuta¹⁴, Yuki Kinoshita¹⁵, Chiharu Tateishi¹⁵, Aya Yamamoto¹⁶, Akimichi Morita¹⁶, Haruna Matsuda-Hirose¹⁷, Yutaka Hatano¹⁷, Hiroshi Kawasaki¹⁸, Keiji Tanese¹⁸, Mamitaro Ohtsuki¹⁹, Koji Kamiya¹⁹, Yudai Kabata²⁰, Riichiro Abe²⁰, Hiroshi Mitsui²¹, Tatsuyoshi Kawamura²¹, Gaku Tsuji¹, Norito Katoh¹², Masutaka Furue¹

Affiliations

¹ Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
² Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School, Saga, Japan.
³ Department of Oral Microbe Control, Graduate School of Medicine, Osaka University, Osaka, Japan.
⁴ Department of Dermatology, Nippon Medical School, Tokyo, Japan.
⁵ Department of Dermatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
⁶ Department of Dermatology, Osaka Habikino Medical Center, Osaka, Japan.
⁷ Department of Dermatology, Shimane University Faculty of Medicine, Shimane, Japan.
⁸ Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
⁹ Department of Dermatology, St. Marianna University School of Medicine, Kanagawa, Japan.
¹⁰ Department of Dermatology, Kochi Medical School, Kochi, Japan.
¹¹ Department of Dermatology, Course of Integrated Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
¹² Department of Dermatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
¹³ Department of Dermatology, Nagoya University Graduate School of Medicine, Aichi, Japan.
¹⁴ Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
¹⁵ Department of Dermatology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
¹⁶ Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan.
¹⁷ Department of Dermatology, Faculty of Medicine, Oita University, Oita, Japan.
¹⁸ Department of Dermatology, School of Medicine, Keio University, Tokyo, Japan.
¹⁹ Department of Dermatology, Jichi Medical University, Tochigi, Japan.
²⁰ Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
²¹ Department of Dermatology, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.

PMID: 36524532
DOI: 10.1111/cea.14267

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized / adverse effects
Biomarkers
Dermatitis, Atopic* / chemically induced
Dermatitis, Atopic* / drug therapy
Humans
Severity of Illness Index
Treatment Outcome

Substances

dupilumab
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal
Biomarkers